Transdermal Estradiol with Micronized Progesterone: Optimal Hormone Therapy for Perimenopause – RCT

This randomized controlled trial evaluated the efficacy and safety of various hormone replacement therapy (HRT) regimens in 840 perimenopausal women aged 45-55 years. Participants were allocated to receive either transdermal 17β-estradiol with micronized progesterone, oral conjugated estrogens with medroxyprogesterone acetate, transdermal estradiol with dydrogesterone, or non-hormonal therapy for 24 months. Vasomotor symptom reduction was the main result, with safety profiles, metabolic paramete